Nyrada Inc (NYR)

Snapshot

NYR's Principal Activity is the development of therapeutic treatments for cardiovascular, neurological and inflammatory/autoimmune diseases, testing and optimization of novel drug candidates while building on the Company's patent portfolio.

Announcements

Corporate Overview

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date	Amount	Franking	Gross	Type	Payable
No dividends paid.

Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Name	Title	Since	Bio
Dr Ian Edward Dixon	Founder,Non-Executive Director	Sep 2020	Dr Ian Edward Dixon Founder,Non-Executive Director Mr Dixon, In 2011, Co-Founded Cynata Inc, a company that is progressing the commercialisation of what has become the Cymerus technology of ASX-listed Cynata Therapeutics Ltd (ASX-CYP). Dr Dixon is a co-inventor of the LEAP Technology owned by Exopharm. Dr Dixon brings to the Board a technical and entrepreneurial background in founding, building and running technology-based companies, in recognising the potential commercial value of early-stage drug development, and in understanding the challenges involved in drug development. Dr Dixon is also a founder of Exopharm Ltd. During the last three years, Dr Dixon has served as a director of the following listed companies: Medigard Ltd (ASX:MGZ) and Noxopharm Ltd (ASX:NOX
Mr Christopher Cox	Non-Executive Director	Nov 2019	Mr Christopher Cox Non-Executive Director Mr Cox is a Co-Founder and Managing Partner of Population Health Partners, L.P., a global private equity firm focused on innovative therapeutics with the potential to transform health outcomes for populations. Prior to that, from January 2012 to February 2020, he was a partner at Cadwalader, Wickersham & Taft LLP, where he also served as the Chairman of Cadwalader's Corporate Department and as a member of its Management Committee. He remains a Senior Attorney of Cadwalader. From February 2016 to March 2019, Chris was seconded to The Medicines Company, a global biopharmaceutical company, where he served as Executive Vice President and Chief Corporate Development Officer and was responsible for business development and strategy. Prior to January 2012, he was a partner at Cahill Gordon & Reindel LLP. He also serves as the Chief Executive Officer of Symphony Capital Holdings, LLC, a private investment holding company with interests in life sciences, entertainment and technology
Mr John Alexander Moore	Non-Executive Chairman,Non-Executive Director	Jun 2019	Mr John Alexander Moore Non-Executive Chairman,Non-Executive Director Mr Moore currently serves as Chairman of Trialogics, a clinical trial informatics business and Chairman of Scientific Industries (SCND-OTCQB) a producer of laboratory instruments for the life sciences industry. He was CEO of Acorn Energy from 2006 to 2015, during which time the CoaLogix business was acquired for US$11 million and sold for US$101 million, and the Comverge business listed in the US before its sale to Constellation Energy. In 2002 he was a Partner and CEO of Edson Moore Healthcare Ventures and acquired for US$148 million a portfolio of sixteen drug delivery investments from Elan Pharmaceuticals.
Mr Ruediger Weseloh	Non-Executive Director	Jun 2019	Mr Ruediger Weseloh Non-Executive Director Mr Weseloh is a Senior Director of Business Development at Merck KgaA, Darmstadt, Germany, where over a period of 15 years he has led more than 60 transactions for its pharmaceutical division, completing deals across the drug development value chain in the fields of Oncology, Rheumatology, Neurodegenerative diseases, and Fertility. Before Merck KgaA, Dr Weseloh spent 5 years as a Biotech/Pharma Equity Analyst at Gontard & Metallbank AG, Frankfurt, and Sal. Oppenheim, Cologne/Frankfurt, as well as 3 years as a Postdoc at the Max-Planck-Institute for Experimental Medicine in Goettingen Dr Weseloh also serves on the Supervisory Board of Cytotools AG, Freiburg, German
Mr Marcus Frampton	Non-Executive Director	Jun 2019	Mr Marcus Frampton Non-Executive Director Mr Frampton currently serves as the Chief Investment Officer of the Alaska Permanent Fund Corporation (APFC), the US$82 billion sovereign wealth fund for the State of Alaska. Mr Frampton manages the investment team at APFC and leads all investment decisions related to APFC's investment portfolio within the guidelines established by APFC's Board of Trustees. Before joining the APFC in 2012, Mr Frampton held positions ranging from Investment Banking Analyst & Associate at Lehman Brothers (2002-2005), to private equity investing at PCG Capital Partners (2005-2010), and acted as an executive of a private equity-backed portfolio company at LPL Financial (2010-2012). In addition to his duties at the APFC, Mr Frampton is also a shareholder and sits on the board of directors of Scientific Industries, Inc., a leading manufacturer of laboratory equipment and the owner of intellectual property related to bioprocessing systems
Mr Peter Ashley Marks	Non-Executive Director	Aug 2017	Mr Peter Ashley Marks Non-Executive Director Mr Marks has over 35 years' experience in corporate advisory and investment banking. Throughout his long career, he has specialised in capital raising, IPOs, cross border M&A transactions, corporate underwriting, and venture capital transactions for companies in Australia, the US and Israel. He has been involved in a broad range of transactions with a special focus on the life sciences, biotechnology, medical technology and high-tech segments. He has served as both an Executive and Non-Executive Director of several different entities which have been listed on the ASX, NASDAQ, and AIM markets. He is currently a Director of Alterity Therapeutics Limited (ASX:ATH and NASDAQ:ATHE), Non-Executive Director of Noxopharm Limited (ASX: NOX) and Non-Executive Director of Elsight Ltd (ASX:ELS). Until 31 March 2020, he was also a Non-Executive Director of Fluence Corporation Ltd (ASX: FLC).
Mr David James Franks	Company Secretary	N/A
Mr James Bonnar	Chief Executive Officer	N/A

Show All

Director Transactions

Date	Director	Type	Amount	Price	Value	Notes
29/06/21	John Moore	Issued	76,923	$0.26	$20,000	Placement
29/06/21	Peter Marks	Issued	200,000	$0.26	$52,000	Placement
29/06/21	Marcus Frampton	Issued	75,000	$0.26	$19,500	Placement
29/06/21	Ruediger Weseloh	Issued	100,000	$0.26	$26,000	Placement
29/06/21	Ian Dixon	Issued	192,308	$0.26	$50,000	Placement
29/06/21	Christopher Cox	Issued	625,000	$0.26	$162,500	Placement
02/03/21	John Moore	Buy	+19,000	$0.35	$6,650	On-market trade
02/03/21	John Moore	Buy	+500	$0.204	$102	As advised by the company
23/02/21	Marcus Frampton	Buy	+25,000	$0.357	$8,925	On-market trade
18/01/21	Ian Dixon	Issued	1,800,000	$0.40	$720,000	Director remuneration
25/11/20	John Moore	Buy	+32,000	$0.206	$6,600	On-market trade
24/11/20	Marcus Frampton	Buy	+35,000	$0.21	$7,350	On-market trade
10/09/20	John Moore	Buy	+32,500	$0.21	$6,825	On-market trade
23/04/20	John Moore	Buy	+35,000	$0.168	$5,882	On-market trade

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
Marcus Frampton	30/06/2021	245,075	N/A	1,800,000	N/A
Christopher Cox	30/06/2021	N/A	1,425,000	1,800,000	N/A
Ruediger Weseloh	30/06/2021	100,000	N/A	1,800,000	N/A
John Moore	30/06/2021	358,423	N/A	3,600,000	N/A
Ian Dixon	30/06/2021	N/A	10,114,033	5,999,400	N/A
Peter Marks	30/06/2021	N/A	250,000	2,600,000	N/A

Show All

Top 20 Shareholders

About the Data

Name	Shares	Capital
Noxopharm Limited	33,373,245	21.39%
Altnia Holding Pty Ltd (I Dixon Family A/C)	9,921,725	6.36%
Sunset Capital Management Pty Ltd (Sunset Superfund A/C)	2,548,197	1.63%
Colin Housely & Freda Housely(Cm Housley & Fv Housley Fam)	1,863,725	1.19%
Kohen Enterprises Pty Ltd	1,735,000	1.11%
Canary Capital Pty Ltd	1,701,923	1.09%
Symphony Capital Holdings Llc	1,425,000	0.91%
Professor Gary David Housley	1,411,411	0.90%
Kyriaco Barber Pty Ltd	1,400,000	0.90%
John W King Nominees Pty Ltd	1,242,483	0.80%
Goodridge Foundation Pty Ltd (Goodridge Foundation A/C)	1,212,416	0.78%
Dixson Trust Pty Limited	1,100,000	0.71%
Mr Graham Arthur Robinson	1,082,888	0.69%
Himstedt & Co Pty Ltd (The Himstedt Family A/C)	1,057,000	0.68%
Rhlc Pty Limited (Rhlc S/F A/C)	1,000,000	0.64%
Mr Michael Francis Mcmahon & Mrs Susan Lesley Mcmahon (Mcmahon Super Fund A/C)	924,616	0.59%
Mr Jason Fernando Haddock	873,146	0.56%
Sandhurst Trustees Ltd (Wunala Capital A/C)	831,250	0.53%
Mr Anthony John Locantro	734,540	0.47%
Mr John Gardner	734,384	0.47%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
2020	$0.175	30 June

NYR Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.